Snapshot Proteomics™ is a sensitive and reproducible technology that uses microarrays containing ~20,000 individual human proteins to naturally reveal information about complex mixtures like cells or serum.
When a microarray is exposed to a biological sample, the proteins on the chip take on the same post-translational modifications and engage in the same protein-protein interactions as their endogenous counterparts within that sample. We extract this crucial information by developing the arrays in a method analogous to a western blot. Improved sensitivity is afforded by enzymatic amplification, and our process requires no harsh manipulation that could lead to data loss such as the trypsin digestion. Unlike a western blot, Snapshot Proteomics™ enables novel discovery by starting with up to 20,000 human proteins identifiable by location and does not depend upon detection reagents specific to individual proteins.
Features:
- Reproducibility from biological duplicates is <50% for MS/MS, >90% for Snapshot Proteomics
- The best MS/MS runs return information on a few thousand of the most abundant proteins. Each and every single experiment utilizing Snapshot Proteomics™ provides information on up to 20,000 human proteins without bias to cellular concentration
Customizable services which utilize Snapshot Proteomics™:
- U.M.A.P™ reveals changes to the proteome of manipulated cells or specific protein interactions of purified protein samples. For example, if experimentally manipulated cells are provided, changes in post-translational modification across ~20,000 human proteins can be determined.
- S.M.A.R.T™ can be used for the preclinical development of lead compounds. SMART™ uses Snapshot Proteomics™ to reveal changes to the proteome of pharmacologically treated cells. This information is then analyzed with aproprietary database to gain deeper understanding of the proteomic molecular mechanisms.
- ProActiN™ is a specialized tool for clinical biomarker discovery that uses Snapshot Proteomics™ to provide information about changes to the proteome of dosed individuals. Specifically, ProActiN™ compares the differences in post-translational modification between related samples, such as a treated group vs. a control group, or responders vs. non-responders, to discover molecular signatures that can be prospectively used to identify one of the sample cohorts.